Celularity Inc. Deferred State and Local Income Tax Expense (Benefit)
Celularity Inc. (CELU) reported Deferred State and Local Income Tax Expense (Benefit) of $2.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-30.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit · last filed 2026-04-30
- Celularity Inc. deferred state and local income tax expense (benefit) for fiscal 2025 was $2.00K.
- Celularity Inc. deferred state and local income tax expense (benefit) for fiscal 2024 was -$1.00K.
- Celularity Inc. deferred state and local income tax expense (benefit) for fiscal 2023 was -$1.00K.
- Celularity Inc. deferred state and local income tax expense (benefit) for fiscal 2022 was -$1.00K, a 150.00% decline from fiscal 2021.
| Period end | Deferred State and Local Income Tax Expense (Benefit) 12 month |
|---|---|
| 2025-12-31 | $2.00K 10-K · filed 2026-04-30 |
| 2024-12-31 | -$1.00K 10-K · filed 2026-04-30 |
| 2023-12-31 | -$1.00K 10-K · filed 2025-05-08 |
| 2022-12-31 | -$1.00K 10-K · filed 2024-07-30 |
| 2021-12-31 | $2.00K 10-K · filed 2023-03-31 |
| 2020-12-31 | -$2.35M 10-K · filed 2022-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |